Northerner
Admin (Retired)
- Relationship to Diabetes
- Type 1
Shares in Irish drug development company Merrion Pharmaceuticals jumped by 25% yesterday on the back of news that the firm has moved a step closer to playing a pivotal role in transforming diabetes medication.
The Dublin-headquartered firm announced yesterday that its main strategic partner, Danish healthcare company, Novo Nordisk has successfully completed an early-stage study into an oral insulin treatment being worked on by the two companies.
If successful the treatment ? which currently has the in-trial codename of ?NN1954? ? would be the first of its kind commercially available.
Merrion last year froze its own drug development programme and repositioned itself as a technology/intellectual property provider to other firms.
Its patented GIPET technology goes into the making of drugs delivered in tablet, capsule or injection form.
http://www.irishexaminer.com/business/merrion-up-25-on-insulin-study-226032.html
The Dublin-headquartered firm announced yesterday that its main strategic partner, Danish healthcare company, Novo Nordisk has successfully completed an early-stage study into an oral insulin treatment being worked on by the two companies.
If successful the treatment ? which currently has the in-trial codename of ?NN1954? ? would be the first of its kind commercially available.
Merrion last year froze its own drug development programme and repositioned itself as a technology/intellectual property provider to other firms.
Its patented GIPET technology goes into the making of drugs delivered in tablet, capsule or injection form.
http://www.irishexaminer.com/business/merrion-up-25-on-insulin-study-226032.html